Structural factors influencing potency of currently used acetylcholinesterase reactivators for treatment of cyclosarin intoxications

Current Pharmaceutical Design

Volumn 13, Issue 33, 2007, Pages 3445-3452

  Kuca, Kamil ^a   Jun, Daniel ^a   Bajgar, Jiri ^a  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Acetylcholinesterase; Antidotes; Cyclosarin; Nerve agent; Oxime; Reactivators

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; CHLORPYRIFOS; CHOLINESTERASE REACTIVATOR; CYCLOSARIN; DYFLOS; ENZYME ACTIVATOR; K 027; K 033; K 048; K 074; K 100; K 101; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; OBIDOXIME; PARATHION; PRALIDOXIME; SARIN; SOMAN; TABUN; TRIMEDOXIME; UNCLASSIFIED DRUG;

COMPUTER AIDED DESIGN; COMPUTER MODEL; DRUG ADSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME REACTIVATION; HUMAN; INTOXICATION; LIVER DYSFUNCTION; LIVER TOXICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ANALYSIS;

EID: 36749013578     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782360546     Document Type: Review

References (107)

1. Bajgar J. Organophosphates/nerve agent poisoning: Mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 2004; 38: 151-216.
2. Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993; 58: 51-66
3. Black RM, Clarke RJ, Read RW, Reid MT. Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to the analysis of chemical warfare samples, found to contain residues of the nerve agent sarin, sulphur mustard and their degradation products. J Chromatogr A 1994; 662: 301-21.
4. Bolz F, Dudonis KJ, Schulz DP. The counterterrorism Handbook - Tactics, Procedures, and Techniques, 2002, CRC Press.
5. Patocka J, Kuca K, Jun D. Acetylcholinesterase: Crucial enzyme of human body. Acta Medica (Hradec Kralove) 2004; 47: 215-30.
6. Patocka J, Cabal J, Kuca K, Jun D. Oxime reactivation of acetylcholinesterase inhibited by toxic phosphorus ester: In vitro kinetics and thermodynamics. J Appl Biomed 2005; 3: 91-9.
7. Taylor P. The pharmacological basis of therapeutics 1996, McGraw Hill.
8. Bajgar J, Fusek J, Kuca K, Bartosova L, Jun D. Treatment of organophosphate intoxication using cholinesterase reactivators: Facts and fiction. Mini Rev Med Chem 2007; 7, 461-6.
9. Thiermann H, Szinicz L, Eyer F, Worek F, Eyer P, Felgenhauer N, et al. Modern strategies in therapy of organophosphate poisoning. Toxicol Lett 1999; 107: 233-9.
10. van Helden HPM, Busker RW, Melchers BPC, Bruijnzeel PLB. Pharmacological effects of oximes: How relevant are they? Arch Toxicol 1996; 70: 779-86.
11. Buckley NA, Eddleston M, Szinicz L. Oximes for acute organophosphate pesticide poisoning. The Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD005085. DOI: 10.1002/14651859.CD005085.
12. Dawson RM. Review of oximes available for treatment of nerve agent poisoning. J Appl Toxicol 1994; 14: 317-31.
13. Pang YP, Kollmeyer TM, Hong F, Lee JC, Hammond PI, Haugabouk SP, et al. Rational design of alkylene-linked bispyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol 2003; 10: 491-502.
14. Yang GY, Yoon JH, Seong CM, Park NS, Jung YS. Synthesis of bis-pyridinium oxime antidotes using bis(methylsulfonoxymethyl) ether for organophosphate nerve agents. Bull Korean Chem Soc 2003; 24: 1368-70.
15. Kim TH, Kuca K, Jun D, Jung YS. Design and synthesis of new bis-pyridinium oximes as cyclosarin-inhibited acetylcholinesterase reactivators. Bioorg Mod Chem Lett 2005; 15: 2914-7.
16. Picha J, Kuca K, Kivala M, Kohout M, Cabal J, Liska F. New group of monoquaternary reactivators of the acetylcholinesterase inhibited by nerve agents. J Enzyme Inhib Med Chem 2005; 20: 233-7.
17. Musilek K, Kuca K, Jun D, Dohnal V, Dolezal M. Synthesis of the novel series of bispyridinium compounds bearing xylene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylchohnesterase. J Enzyme Inhib Med Chem 2005; 20: 409-15.
18. Musilek K, Kuca K, Jun D, Dobnal V, Dolezal M. Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase. Biorg Med Chem Lett 2006; 16: 622-7.
19. Worek F, Kirchner T, Bäcker M, Szinicz; L. Reactivation by various oximes of human erythrocyte acetylcholinesterase inhibited by different organophosphorus compounds. Arch Toxicol 1996; 70: 497-503.
20. Kuca K, Bielavsky J, Cabal J, Kassa J. Synthesis of a new reactivator of tabun-inhibited acetylcholinesterase. Bioorg Med Chem Lett 2003; 13: 3545-7.
21. Cabal J, Kuca K, Kassa J. Specification of the structure of oximes able to reactivate tabun inhibited acety1cholinesterase. Bas Clin Pharmacol Toxicol 2004; 95: 81-6.
22. Worek F, Widmaan R, Knopff O, Szinicz L. Reactivating potency of obidoxime, pralidoxime, HI-6 and HLö-7 in human erythrocyte acetylcholinesterase inhibited by highly toxic organophosphorus compounds. Arch Toxicol 1998; 72: 237-43.
23. Petroianu GA, Arafat K, Kuca K, Kassa J. Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: in vitro reactivation of red blood cell acety1cholinesterase inhibitied by paraoxon. J Appl. Toxicol 2006; 26: 64-71.
24. Kuca K, Cabal J, Sevelova L, Jun D, Krejcova G. Reactivation of acety1cholinesterase from different species inhibited by nerve agent sarin. Drug Met Rev 2004; 36(Suppll): 658.
25. Petroianu GA, Hasan MY, Nurulain SM, Arafat K, Shafiullah M, Naseer O. Protective agents in acute high-dose organophosphate exposure: comparison of ranitidine with pralidoxime in rats. J Appl Toxicol 2005; 25: 68-73.
26. Kuca K, Cabal J, Kassa J, Jun D, Hrabinova M. A comparison of in vitro potency of currently available oximes (pralidoxime, obidoxime, HI-6) to reactivate sarin-inhibited acetylcholinesterase in various parts of pig brain. J Appl Toxicol 2005; 25: 271-6.
27. Kassa J, Cabal J. A comparison of the efficacy of a new asymmetric bispyridinium oxime BI-6 with currently available oximes and H oximes against soman by in vitro and in vivo methods. Toxicology 1999; 132:111-8.
28. Kassa J, Cabal J. A comparison of the efficacy of a new asymmetric bispyridinium oxime BI-6 with presently used oximes and H oximes against sarin by in vitro and in vivo methods. Hum Exp Toxicol 1999; 18: 560-5.
29. Kuca K, Kassa J. Oximes-inducod reactivation of rat brain acetylcholinesterase inhibited by VX agent. Hum Exp Toxicol 2004; 23: 167-71.
30. Koplovitz I, Stewart JR. A comparison of the efficacy of HI-6 and 2-PAM against soman, sarin and VX in the rabbit. Toxicol Lett 1994; 70:269-79.
31. Clement JG, Shiloff JD, Gennings C. Efficacy of a combination of acetylcholinesterase reactivators, HI-6 and obidoxime, against tabun and soman poisoning in mice. Arch Toxicol 1987; 61: 70-5.
32. Puu. G, Artursson E, Bucht G. Reactivation of nerve agent inhibited acety1cholinesterases by HI-6 and obidoxime. Biochem Pharmacol 1986; 35: 1505-10.
33. Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 2003; 22: 165-90.
34. Bartosova L, Kuca K, Jun D, Kunesova G. Bispyridinium oximes as antidotal treatment of cyclosarin poisoning - in vitro and in vivo testing. Inter J Toxicol 2005; 24: 399-402.
35. Kassa J. Comparison of the effects, of BI-6, a new asymmetric bipyridine oxime, with HI-6 oxime and obidoxime in combination with atropine on soman and fosdrine toxicity in mice. Ceska Slov Farm 1999; 48: 44-7.
36. Kassa J, Bajgar J. The influence of pharmacological pretreatment on efficacy of HI-6 oxime in combination with benactyzine in soman poisoning in rats. Hum Exp Toxicol 1996, 15: 3 83-8.
37. Koplovitz I, Menton R, Matthews C, Shutz M, Nalls C, Kelly S. Dose-response effects of atropine and HI-6 treatment of organophosphorus poisoning in guinea pigs. Drug Chem Toxicol 1995; 18: 119-36.
38. Luo Ch, Leader H, Radic Z, Maxwell DM, Taylor P, Doctor BP, et al. Two possible orientations of the HI-6 molecule in the reactivation of organophosphate-inhibited acetylcholinesterase. Biochem Pharmacol 2003; 66: 387-92.
39. Jokanovic M, Maksimovic M. A comparison of trimedoxime, obidoxime, pralidoxime and HI-6 in the treatment of oral organophosphorus insecticide poisoning in the rat. Arch Toxicol 1995; 70: 119-23.
40. Kuca K, Cabal J, Patocka J, Kassa J. Synthesis of bisquatemary symmetric - X,δ-bis(2-Hydroxyiminomethylpyridinium)alkane dibromides and their reactivation of cyclosarin-inhibited acetylcholinesterase. Lett Org Chem 2004; 1: 84-6.
41. Kuca K, Bielavsky J, Cabal J, Bielavska M. Synthesis of a potential reactivator of acety1cholinesterase 1-(4-hydroxyiminomediylpyridinium)-3- (carbamoylpyridinium)-propane dibromide. Tetrahedron Lett 2003; 44: 3123-5.
42. De Jong LPA, Benschop HP, Van Den Berg GR, Wolring GZ, Korte DC. Reactivation of tabun-inhibited acety1cholinesterase by 1-(hetero)arylmethyl-pyridinium-oximes. Eur J Med Chem - Chim Therap 1981; 16: 257-62.
43. Lucic A, Radic B, Peraica M, Mesic M, Primozic I, Binenfeld Z. Antidotal efficacy of quinuclidinium oximes aganst soman poisoning. Arch Toxicol 1997; 71: 467-70.
44. Kuca K, Cabal J, Jun D, Kassa J, Bartosova L, Kunesova G, et al. Development of new acety1cholinesterase reactivators - antidotes used for treatment of nerve agent poisonings. Biomed Papers 2005; 149: 429-31.
45. Hammond PI, Kern C, Hong F, Kollmeyer TM, Pang YP, Brimijoin S. Cholinesterase reactivation in vivo with a novel bis-oxime optimized by computer-aided design. J Pharmacol Exp Ther 2003; 307: 190-6..
46. Senapati S, Bui JM, McCammon JA. Induced fit in mouse acetyl-cholinesterase upon binding a femtomolar inhibitor: A molecular dynamics study. J Med Chem 2005; 8:8155-62.
47. Wiesner J, Kriz Z, Kuca K, Jun D, Koca J. Acetylcholinesterases- the structural similarities and differences. J Enzyme Inhib Med Chem 2007; 22: 417-24.
48. Dohnal V, Kuca K, Jun D. Prediction of a new broad-spectrum reactivator capable to reactivate acetylcholinesterase inhibited by nerve agents. J Appl Biomed 2005; 3: 139-45.
49. Dohnal V. Kuca K, Jun D. What are artificial neural networks and what they can do? Biomed Papers 2005; 149: 221-24.
50. Mager PP. QSAR applied to aging of phosphylated acetylcholinesterase. Pharmazie 1983; 38: 271-2.
51. Mager PP. Quantitative structure-reactivity and structure-toxicity relationships of reactivators of phosphylated acetylcholinesterase. Pharmazie 1981; 36: 450-1.
52. Mager PP, Weber A. Structural bioinformatics and QSAR analysis applied to the acetylcholinesterase and bispyridinium aldoximes. Drug Des Dis 2004; 18: 127-50.
53. Ellman GL, Courtney DK, Andres V, Feartherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-93.
54. Wang EIC, Braid PE. Oxime reactivation of diethylphosphoryl human serum cholinesterase. J Biol Chem 1968; 242: 2683-6.
55. Sevelova L, Kuca K, Krejcova G, Vachek J. Therapeutic efficacy of oxime treatment in cyclosarin-poisoned mice pretreated with a combination of pyridostigmine, benactyzine and trihexyphenidyl. J Appl Biomed 2004; 2: 163-7.
56. Sevelova L, Bajgar J, Saxena A, Doctor BP. Protective effect of equine butyrylchohnesterase in inhalation intoxication of rats with sarin: determination of blood and brain cholinesterase activities. Inhal Toxicol 2004; 16: 531-6.
57. Bajgar J, Fusek J, Vachek J. Treatment and prophylaxis against nerve agent poisonong. ASA Newslett 1994; 94: 10.
58. Das Gupta S, Bhattacharya R, Purnanand B, Pant P. Protection studies on anticholinesterase agents in rats. Pharmazie 1990; 10: 45-6.
59. Krejcova-Kunesova G, Bartosova L, Kuca K. Signs of cyclosarin-induced neurotoxicity and its pharmacological treatment with quaternary pyridinium-oxines reactivators. Toxicology 2005; 216: 32-40.
60. Krejcova G, Kassa J. Anticholinergic drugs-functional antidotes for the treatment of tabun intoxication. Acta Medica (Hradec Kralove) 2004; 47: 13-8.
61. Bajgar J, Herink J. Continual monitoring of the rat bloode cholinesterase activity in vivo following administration of different inhibitors. Toxicol Lett 1995; 78(Suppl 1): 18.
62. Balali-Mood M, Shariat M. Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effects of oximes. J Physiology (Paris) 1998; 92: 375-8.
63. Bismuth C, Ins RH, Marrs TC. Efficacy, toxicity and clinical use of oxime in anticholinesterase poisoning, In: Ballantyne B, Marrs TC, Aldrige WN, Eds, Clinical and experimental toxicology of organophosphates and carbamates, Butterworth-Heinmann Ltd., Oxford, 1992, pp. 555-577.
64. Nocentini S, Moreno G, Petit PX, Guggiari M, Salet C, Demerseman P, et al. Induction of mitochondrial dysfunction and apoptisis in HeLa Cells by bis-pyridinium Oximes, a newly synthesized family of lipophilic biscations. Biochem Pharmacol 1997; 53: 1543-52.
65. Kolka MA, Cadarette BS. Heat exchange after cholinolytic and oxime therapy in protective clothing. Mil Med 1990; 155: 390-4.
66. Jun D, Kuca K, Hronek M, Opletal L. Effect of some acetylcholinesterase reactivators on human platelet aggregation in vitro. J Appl Toxicol 2006; 26: 262-8.
67. Krejcova G, Kuca K, Sevelova L. Cyclosarin - current position of an organophosphate nerve agent. Def Sci J 2005, 55: 105-15.
68. Gee J. Iraqui declaration of chemical weapons: How much did they have and and what was it? Fourth International Symposium on Protection Against Chemical Warfare Agents, June 8-12, 1992, Stockholm, Sweden.
69. Coleman IW, Patton GE, Bannard RA. Cholinolytics in the treatment of anticholinesterase poisoning. V. The effectiveness of Parpanit with oximes in the treatment of organophosphorus poisoning. Can J Physiol Pharmacol 1968; 46: 109-17.
70. Koplovitz I, Gresham VC, Dochterman LW, et al. Evaluation of the toxicity, pathology, and treatment of cyclohexyhnethylphosphonofluoridate (CMPF) poisoning in rhesus monkeys. Arch Toxicol 1992; 66: 622-628.
71. Luo C, Liang J. Evaluation of combined toxic effects of GB/GF and efficacy of Jielin Injection against combined poisoning in mice. Toxicol Lett 1997; 92: 195-200.
72. Bartosova-Sevelova L, Kunesova-Krejcova G, Kuca K, Vachek J. Therapeutic efficacy of different antidotal mixtures against poisoning with GF-agent in mice. Acta Medica (Hradec Kralove) 2004; 47: 251-3.
73. Kassa J, Cabal J. A comparison of the efficacy of acetylcholine reactivators against cyclohexyl methylphosphonofluoridate (GF agent) by in vitro and in vivo methods. Pharmacol Toxicol 1999; 84: 41-45.
74. Bartosova L, Kuca K, Kunesova G. Testing of new acetylcholinesterase reactivators as therapy for cyclosarin intoxications. Zprav Voj Farm 2004; 14: 11-5 (In Czech).
75. Kuca K, Patocka J. Reactivation of cyclosarin-inhibited rat brain acetylcholinesterase by pyridinium-oximes. J Enzyme Inhib Med Chem 2004; 19: 39-43.
76. Kuca K, Jun D, Musilek K. Structural requirements of acetylcholinesterase reactivators. Mini Rev Med Chem 2006; 6, 269-77.
77. Stalc A, Sentjurc M. A contribution, to the mechanism of action of SAD-128. Biochem Pharmacol 1990; 40: 2511-7.
78. Schalk I, Ehret-Sabatier L, Le Feuvre Y, Bon S, Massoulie J, Goeldner M. 6-Coumarin diazonium salt: A specific affinity label of the Torpedo acetyleholinesterase peripheral site. Mol Pharmacol 1995; 48: 1063-7
79. Simeon-Rudolf, Reiner E, Skrinjaric-Spoljar M, Radic B, Lucic A, Primozic I, et al. Quinuclidiniumimidazolium compounds: Synthesis, mode of interaction with acetyleholinesterase and effect upon soman intoxicated mice. Arch Toxicol 1998; 72: 289-5.
80. Skrinjaric-Spoljar M, Burger N, Lovric J. Inhibition of acetylcholinesterase by three newpyridinium compounds and their effect on phosphonylation of the enzyme. J. Enzyme Inhib Med Chem 1999; 14: 331-41.
81. Sevelova L, Kuca K, Krejcova G. Antidotal treatment of GF-agent intoxication in mice with new bispyridinium oximes. Toxicology 2005; 207: 1-6.
82. Patocka J, Bielavsky J. Affinity of bis-quaternary pyridinealdoximes for the active centre of intact and isopropyhnethylphosphonylated acetylcholinesterase. Coll Czech Chem Commun 1972; 37: 2110-6.
83. Hammond PI, Kern C, Hong F, Kollmeyer TM, Pang YP, Brimijoin S. Cholinesterase reactivation in vivo with a novel bis-oxime optimized by computer-aided design. J Pharmacol Exp Ther 2003; 307: 190-6.
84. Kuca K, Patocka J, Cabal J. Reactivation of organophosphate inhibited acetylcholinesterase activity by α,ω-bis-(4-hydroxyiminomethylpyridinium)alkanes in vitro. J Appl Biomed 2003; 1: 207-11.
85. Kuca K, Pícha J, Cabal J, Liska F. Synthesis of the three mono-pyridinium oximes and evaluation of their potency to reactivate acetylcholinesterase inhibited by nerve agents. J Appl Biomed 2004; 2: 51-6.
86. Kuca K, Patocka J, Cabal J, Jun J. Reactivation of organophosphate-inhibited acetylcholinesterase by quaternary pyridinium aldoximes. Neurotox Res 2004; 6: 565-70.
87. Doctor BP, Saxena A. Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 2005; 157-158: 167-71.
88. Masson P, Josse D, Lockridge 0, Viguie N, Taupin C, Buhler C. Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning. J Physiol Paris 1998; 92: 357-62.
89. Miller SA, Blick DW, Kerenyi SZ, Murphy MR. Efficacy of physostigmine as a pretreatment for organophosphate poisoning. Pharmacol Biochem Behav 1993; 44: 343-7.
90. Grunwald J, Raveh L, Doctor BP, Ashani Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci 1994; 54: 991-7
91. Bajgar J. Prophylaxis against organophosphorus poisoning. J Med Chem Def 2003; 1: 1-15.
92. Kassa J, Vachek J, Bajgar J, Fusek J. A combination of pyridostigmine with anticholinergic drugs: Effective pharmacological pretreatment of soman-poisoned mice. ASA Newslett 2001; 84: 16-9.
93. Dolezal P, Vachek J, Hrabalek A. In: Brain RK, Walters KA Eds, In vitro transdermal permeation of a cholinesterase reactivator HI-6. In Perspectives in Pecutaneous Penetration STS Publishing, Cardiff, 1988; Vol. 6A: Pp. 84.
94. Rotenberg JS, Newmark J. Nerve attack on children: Diagnosis and menagement. Pediatrics 2003; 112: 648-58.
95. Shih TM, Dun o SM, Mc Donough JH. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol Appl Pharmacol 2003; 188: 69-80.
96. Shih TM, McDonough JH, Koplovitz I. Anticonvulsants for soman-induced seizure activity. J Biomed Sci 1999; 6: 86-96.
97. Chennamaneni SR, Venkateswarlu V, Achaiah G. Quaternary salts of 4,3′ and 4,4′ bis-pyridinium monooximes: Synthesis and biological activity. Bioorg Med Chem Lett 2005; 15: 3076-80.
98. Chennamaneni SR, Venkateswarlu V, Achaiah G. Quaternary salts of 4,3′ and 4,4′bis-pyridinium monooximes. Part 2: Synthesis and biological activity. Bioorg Med Chem Lett 2006; 16: 2134-8.
99. Oh KA, Yang GY, Jun D, Kuca K, Jung YS. Bis-pyridiumaldoxime reactivators connected with CH(2)0(CH(2))(n)OCH(2) linkers between pyridinium rings and their reactivity against VX. Bioorg Med Chem Lett 2006; 16: 4852-5.
100. Cassel GE, Fosbraey P. Measurement of the oxime HI-6 after peripheral administration in tandem with neurotransmitter levels in striatal dialysates: Effects of soman intoxication. J Pharmacol Toxicol Methods 1996; 35: 159-66.
101. Sakurada K, Matsubara K, Shimizu K, Shiono H, Seto Y, Tsuge K, et al. Pralidoxime iodide (2-Pam) penetrates across the blood-brain barrier. Neurochem Res 2003; 28: 1401-7.
102. Bajgar J, Jakl A, Hrdina V. The influence of obidoxime on acetyl-cholinesterase activity in different parts of the mouse brain following isopropylmethyl phosphonofluoridate intoxication. Eur J Pharmacol 1972; 19: 199-202.
103. Bajgar J, Jakl A, Hrdina V. Influence of trimedoxime and atropine on acetlycholinesterase activity in some parts of the brain of mice poisoned by isopropyl-methyl-phosphonofluoridate. Bioch Pharmacol 1971; 20: 3230-3.
104. Bajgar J. The influence of inhibitors and other factors on cholinesterases. Sbor Ved Praci LF UK Hradec Kralove 1991; 34: 3-77.
105. Barnard DL. Current status of anti-picomavirus therapies. Curr Pharm Des 2006; 12(11): 1379-90.
106. D'Andrea MR, Nagele RG. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Des 2006; 12(6): 677-84.
107. Johnson G, Moore SW. The peripheral anionic site of acetylcholinesterase: Structure, functions and potential role in rational drug design. Curr Pharm Des 2006; 12(2): 217-25.